Barrostat Medical Inc.
Tissue removal device for use with conventional GI endoscopes. 510(k) regulatory path, reimbursement in place. Possible short term exit.
Tissue resection technology to biopsy dysplastic tissue for the surveillance of Barrett’s esophagus. This resection technology acquirers larger samples than forceps biopsy having the advantage of eliminating the cumbersome, tedious aspects of the current technique. The result is comparable to the Seattle protocol, which provides much greater detection result. Development of the resection capability will lead to a therapeutic ablation option.